Application note: High-throughput IgG quantitation platform for clone screening during drug discovery and development
Posted: 14 July 2021 | Molecular Devices | No comments yet
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
The accurate and reliable measurement of mAb (e.g., IgG) titer is essential in the development and subsequent manufacture to ensure optimal cell culture performance for the production of all biologics. The ability to reliably monitor protein titer in real time throughout a bioprocess allows operators to rapidly adjust the process conditions for maximum protein output while minimizing process time.
Related content from this organisation
- Patient-derived organoids in disease modelling
- The role of CRISPR in microbiome engineering breakthroughs
- Episode 15 – Minimise variability issues in your organoids
- Episode 14 – Complex assays with Ian Shoemaker, Beckman Coulter Life Sciences & Dr Oksana Sirenko, Molecular Devices
- Episode 12 – ELISA assays with Dr Ana Miletic and Anna Dey, Kyowa Kirin & Dr Cathy Olsen, Molecular Devices
Related topics
Analytical Techniques, Antibodies, Assays, Biopharmaceuticals, Disease Research, Genome Editing, Immunology, Lab Automation, Proteomics, Stem Cells, Targets
Related organisations
Molecular Devices